Nachrichten zur Palatin Technologies Inc. Aktie

Palatin expects 225% sequential growth in Vyleesi Q4 sales

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

Gross product sales increased 75% and Prescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J., July 26, 2022 /PRNewswire/ --…

Form 8-K PALATIN TECHNOLOGIES For: Jun 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K PALATIN TECHNOLOGIES For: Jun 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022.…

Palatin Technologies Inc. Q3 loss increases in line with estimates

WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) reported Loss for its third quarter that increased from last year in line…

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results…

Palatin Tech GAAP EPS of -$0.03 beats by $0.01, revenue of $0.22M misses by $1.12M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-Q PALATIN TECHNOLOGIES For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Tech Q3 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Posters highlight Palatins ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J., May 2, 2022 /PRNewswire/ -- Palatin Technologies,…

Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatins…

Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

CRANBURY, N.J., March 3, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based…

Palatin Technologies: A Diamond In The Rough

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin stock positive after FQ2 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K PALATIN TECHNOLOGIES For: Feb 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Recap: Palatin Technologies Q2 Earnings

Palatin Technologies (AMEX:PTN) reported its Q2 earnings results on Tuesday, February 15, 2022 at 07:30 AM. Heres what investors need to…

Palatin Technologies Inc. Q2 Loss misses estimates

WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for second quarter that missed the Street estimates.The companys bottom line…

Palatin Tech GAAP EPS of -$0.04 in-line, revenue of $0.32M beats by $0.18M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

CRANBURY, N.J., Feb. 15, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based…

Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021.…

Form 10-Q PALATIN TECHNOLOGIES For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Tech Q2 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022

CRANBURY, N.J., Feb. 10, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year…

Palatin: Pre-clinical Data Show Positive Effects Of Melanocortins For Ulcerative Colitis

WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN) reported the positive effects of PL8177 on treating ulcerative colitis in an animal…

Palatin to Present at H.C. Wainwright BioConnect Conference

CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines…

Palatin (PTN) Begins Phase III Study For Dry Eye Disease

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from…

Palatin Advances PL9643 For The Treatment Of Dry Eye Disease Into Phase 3 Study

WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) said on Tuesday that it has initiated a pivotal phase III clinical study…

Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease

CRANBURY, N.J., Dec. 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines…

Thinking about buying stock in American Airlines, Palatin Technologies, Blue Owl Capital, Seanergy Maritime, or Li Auto?

NEW YORK, Dec. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, PTN, OWL, SHIP, and LI. To…

Thinking about buying stock in NLS Pharmaceutics, Petros Pharmaceuticals, Palatin Technologies, TG Therapeutics, or Qualigen Therapeutics?

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NLSP, PTPI, PTN, TGTX, and QLGN. To…

Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide

CRANBURY, N.J., Nov. 30, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines…

Palatin Technologies Up 57% On Heavier-Than-Average Volume

Palatin Technologies Up 57% On Heavier-Than-Average Volume...…

Thinking about buying stock in Petros Pharmaceuticals, Palatin Technologies, cbdMD, RLX Technology, or Merck?

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTPI, PTN, YCBD, RLX, and MRK. To…

Biofrontera, Palatin surge amid social media chatter

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Thinking about buying stock in Palatin Technologies, ContextLogic, Nordstrom, Aptevo Therapeutics, or BioNano Genomics?

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTN, WISH, JWN, APVO, and BNGO. To…

Global Porphyria Pipeline Market Research Report 2021 Featuring Agios Pharma, Alnylam Pharma, Clinuvel Pharma, Mitsubishi Tanabe, Moderna, Palatin Technologies, & Recordati Rare Diseases

DUBLIN, Nov. 15, 2021 /PRNewswire/ -- The "Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added…

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2022 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Technologies Inc. Q1 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Palatin Technologies Inc. (PTN):-Earnings: -$7.11 million in Q1 vs. -$3.94 million…

Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

CRANBURY, N.J., Nov. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based…

Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

CRANBURY, N.J., Oct. 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines…

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin shares rise after Q4 results, data timeline updates

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Technologies Inc. Q4 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Palatin Technologies Inc. (PTN):-Earnings: -$13.93 million in Q4 vs. -$7.30 million…

Palatin Tech EPS misses by $0.03, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Tech FQ4 2021 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines…

Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021

CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal…

Palatin to Present Peptides Platform at the TIDES USA Conference

CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines…

Palatin Announces Presentation at the Eyecelerator@ASCRS Conference

CRANBURY, N.J., July 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines…